Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting
Abstract Luspatercept, an erythroid maturation agent, and imetelstat, a first-in-class telomerase inhibitor, have expanded the therapeutic landscape for patients with myelodysplastic neoplasms (MDS). Recent data presented at the 2025 American Society of Hematology (ASH) Annual Meeting further clarif...
I tiakina i:
| Ngā kaituhi matua: | , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2026-06-01
|
| Rangatū: | Journal of Hematology & Oncology |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s13045-026-01815-5 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|